Forward-looking statements: This Annual Report, including the climate-related disclosures made in the Sustainability Report in accordance with AASB S2, contains forward‑looking statements, including statements with respect to CSL’s activities, intentions, objectives, expectations, plans, strategies, future earnings, future capital expenditure, plans, future company compliance and performance. This report also includes forward‑looking statements regarding climate change, climate-related transition planning, climate-related risks and opportunities and other environmental and energy transition scenarios, such as biodiversity. While these forward‑looking statements reflect CSL’s expectations at the date of this Report, they are not guarantees, assurances or predictions of future events or performance. CSL cannot predict whether any forward-looking statements, or the assumptions on which they are based, will eventuate. These statements involve known and unknown risks, which may cause actual results to differ materially from those expressed in the report. Forward-looking statements are based on CSL’s current expectations, best estimates and the judgements, estimates and assumptions as at the date of preparation. These statements are subject to significant risks, uncertainties and contingencies that could cause actual results or outcomes to differ materially, many of which are beyond CSL’s control. A range of factors could cause the Group’s actual results, performances or achievements to differ, possibly materially, from those expressed in the forward‑looking statements. These factors include changes in government and policy; actions of regulatory bodies and other governmental authorities such as changes in taxation or regulation (or approvals under regulation); the effect of economic conditions; technological developments in the healthcare field including the use of Artificial Intelligence (AI); advances in environmental protection processes; and geopolitical developments. There are also limitations with respect to scenario analysis, and it is difficult to predict which, if any, of the scenarios might eventuate. Scenario analysis is not an indication of probable outcomes and relies on assumptions that may or may not prove to be correct or eventuate. Readers are cautioned not to place undue reliance on forward‑looking statements. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update, revise or review any forward‑looking statements (or the assumptions on which they are based) to reflect any change in expectations, contingencies or assumptions, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance. Third party information: Certain market and industry data used in this Annual Report has been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Except where otherwise indicated, CSL has not sought to independently verify market or industry data obtained from public and third-party sources. Non-IFRS financial information: References to AASB refer to the Australian Accounting Standards Board and IFRS refers to the International Financial Reporting Standards. There are references to IFRS and non-IFRS financial information in this report. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies’ information. Non-IFRS financial measures are used to enhance the comparability of information between reporting periods and enable further insight and a different perspective into financial performance. Non-IFRS financial information should be considered in addition to, and is not intended to be a substitute for, IFRS financial information and measures. Non-IFRS financial measures are not subject to audit or review. Disclaimer as it relates to trademarks: Unless otherwise indicated, the trademarks referenced in this report are owned by CSL Limited or other CSL Group companies and are registered in one or more jurisdictions. The following trademarks are owned by CSL partners and registered in one or more jurisdictions: FILSPARI® (TRAVERE THERAPEUTICS, INC.), TAVNEOS® (CHEMOCENTRYX, INC.), RAYALDEE® (EIRGEN PHARMA LTD./OPKO HEALTH, INC.), NEFFY® (ARS PHARMACEUTICALS OPERATIONS, INC.) and RYALTRIS® (GLENMARK SPECIALTY SA). 169
RkJQdWJsaXNoZXIy MjE2NDg3